Bioventus Inc logo

Bioventus Inc - Class A

NEW
NAS:BVS (USA)   Class A
$ 9.78 +0.050 (+0.51%) 10:08 PM EST
23.85
P/B:
3.50
Market Cap:
$ 662.58M
Enterprise V:
$ 944.17M
Volume:
1.42M
Avg Vol (2M):
636.66K
Trade In:
Volume:
1.42M
Avg Vol (2M):
636.66K

Business Description

Bioventus Inc logo
Bioventus Inc
NAICS : 339112 SIC : 3845
ISIN : US09075A1088

Share Class Description:

BVS: Class A

Total Employee Number:

940
Description
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
Name Current Vs Industry Vs History
Cash-To-Debt
0.13
Equity-to-Asset
0.29
Debt-to-Equity
1.44
Debt-to-EBITDA
2.63
Interest Coverage
2.58
Piotroski F-Score
8/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score
1.6
Distress
Grey
Safe
Beneish M-Score
-2.94
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI
83.9
9-Day RSI
68.87
14-Day RSI
60.27
3-1 Month Momentum %
-2.59
6-1 Month Momentum %
20.91
12-1 Month Momentum %
35.44

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
1.69
Quick Ratio
1.13
Cash Ratio
0.24
Days Inventory
182.96
Days Sales Outstanding
79.76
Days Payable
42.51

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-2.6
Shareholder Yield %
8.7

Bioventus Inc Filings

Filing Date Document Date Form
No Filing Data

Bioventus Inc Stock Events

Financials Calendars
Event Date Price ($)
Third quarter earnings conference call for 2026 2026-11-04 08:30 In 130 days
Third quarter earnings results for 2026 2026-11-04 In 129 days
Second quarter earnings conference call for 2026 2026-08-06 08:30 In 40 days
Second quarter earnings results for 2026 2026-08-06 In 39 days
Goldman Sachs Global Healthcare Conference 2026-06-08 16:00 9.04 (+2.15%)
General meeting for 2026 2026-06-03 10:00 8.11 (+2.27%)
First quarter earnings conference call for 2026 2026-05-06 08:30 10.68 (+4.91%)
First quarter earnings results for 2026 2026-05-06 10.68 (+4.91%)
Fourth quarter earnings conference call for 2025 2026-03-05 08:30 8.47 (-3.64%)
Annual report for 2025 2026-03-05 8.47 (-3.64%)
Show
Entries

Guru Commentaries on NAS:BVS

No articles.

Press Release

Subject Date
The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts 2026-06-02
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It 2026-05-22
HALPER SADEH LLC ENCOURAGES BIOVENTUS INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS 2025-12-05
Halper Sadeh LLC Encourages Bioventus Inc. Shareholders to Contact the Firm to Discuss Their Rights 2025-10-22
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm 2023-12-26
BVS Investors Have Opportunity to Lead Bioventus Inc. Securities Fraud Lawsuit 2023-03-03
ROSEN, A GLOBAL AND LEADING FIRM, Encourages Bioventus Inc. Investors with Losses to Secure Counsel Before Important March 13 Deadline in Securities Class Action - BVS 2023-03-02
Deadline in Lawsuit for Investors who Lost over $100,000 in shares of Bioventus Inc. between February 2021 and November 2022 announced by Shareholders Foundation 2023-02-28
BIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bioventus Inc. (NASDAQ: BVS) 2023-02-27
BIOVENTUS DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Bioventus To Contact Him Directly To Discuss Their Options 2023-02-25
10/Page

Articles on Bioventus Inc

No articles.

Headlines

See More
  • 1
No news.
  • 1